Amount of upfront payment received.

No definition available.

Name:	iron_AmountOfUpfrontPaymentReceived
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Business combination consideration transferred contingent consideration.

+ References

No definition available.

+ Details

Name:	iron_BusinessCombinationConsiderationTransferredContingentConsideration
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Business combination contingent consideration sales based milestone payments.

+ References

No definition available.

+ Details

Name:	iron_BusinessCombinationContingentConsiderationSalesBasedMilestonePayments
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Future consideration recievable on clinical.

+ References

No definition available.

+ Details

Name:	iron_FutureConsiderationRecievableOnClinical
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Future consideration recievable on regulatory.

+ References

No definition available.

+ Details

Name:	iron_FutureConsiderationRecievableOnRegulatory
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Future consideration recievable on sales milestones.

+ References

No definition available.

+ Details

Name:	iron_FutureConsiderationRecievableOnSalesMilestones
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Future milestone payment.

+ References

No definition available.

+ Details

Name:	iron_FutureMilestonePayment
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Future milestone recievable.

+ References

No definition available.

+ Details

Name:	iron_FutureMilestoneRecievable
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone payments.

+ References

No definition available.

+ Details

Name:	iron_MilestonePayments
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Non refundable upfront fee.

+ References

No definition available.

+ Details

Name:	iron_NonRefundableUpfrontFee
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Upfront cash payment.

+ References

No definition available.

+ Details

Name:	iron_UpfrontCashPayment
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Upfront non-refundable payment.

+ References

No definition available.

+ Details

Name:	iron_UpfrontNonRefundablePayment
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Upfront payment.

+ References

No definition available.

+ Details

Name:	iron_UpfrontPayment
Namespace Prefix:	iron_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of liability assumed in business combination and recognized at acquisition date.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

+ Details

Name:	us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

+ Details

Name:	us-gaap_SharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

The gain (loss) recognized on initial consolidation of a variable interest entity (VIE) when the VIE is not a business (as defined).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (n)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-22

+ Details

Name:	us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=iron_LicenseAndStockPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iron_AbbvieDeutschlandGmbhCoKgMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=iron_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iron_RocheMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iron_MabwellTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iron_OakBayBiosciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=iron_MergerAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=iron_DevelopmentAndRegulatoryMilestoneFirstIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=iron_DevelopmentAndRegulatoryMilestoneSecondIndicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=iron_DevelopmentAndRegulatoryFirstIndicationFirstMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=iron_DevelopmentAndRegulatoryFirstIndicationSecondMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=iron_DevelopmentAndRegulatorySecondIndicationFirstMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=iron_DevelopmentAndRegulatoryMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=iron_DevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=iron_CommercializationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=iron_Sales-BasedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Licensing Activities and Business Development - Additional Information (Details) - USD ($)			1 Months Ended				3 Months Ended			6 Months Ended		12 Months Ended
	May 27, 2025	Jan. 31, 2025	Oct. 31, 2023	May 31, 2021	Mar. 31, 2021	Sep. 30, 2019	Jun. 30, 2025	Jun. 30, 2024	Mar. 31, 2023	Jun. 30, 2025	Jun. 30, 2024	Dec. 31, 2024	Dec. 29, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Loss from initial consolidation of variable interest entity										$ 852,000	$ 0
Research and development expense							$ 46,319,000	$ 23,485,000		74,082,000	$ 47,189,000
License and Stock Purchase Agreement [Member] \| AbbVie [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Non refundable upfront fee						$ 600,000
License Agreement [Member] \| AbbVie [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment										0
Milestone payments		$ 3,000,000
License Agreement [Member] \| Roche [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares issued													482,313
Future milestone payment										0
Non-refundable upfront payment				$ 4,000,000	$ 500,000
License Agreement [Member] \| Mabwell [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment										0
Upfront payment									$ 10,000,000
License Agreement [Member] \| OBB [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received												$ 200,000
Future milestone recievable										0
License Agreement [Member] \| OBB [Member] \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future consideration recievable on clinical												7,000,000
Future consideration recievable on regulatory												35,000,000
Future consideration recievable on sales milestones												$ 160,000,000
Merger Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent and sales-based milestone payments	$ 50,000,000
Upfront cash payment	0
Acquired assets and assumed liabilities	500,000
Contingent consideration	300,000
Loss from initial consolidation of variable interest entity							900,000			900,000
Development and Regulatory Milestone First Indication [Member] \| License Agreement [Member] \| Roche [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment				50,000,000
Development and Regulatory Milestone Second Indication [Member] \| License Agreement [Member] \| Roche [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment				35,000,000
Development and Regulatory First Indication First Milestone [Member] \| License Agreement [Member] \| Roche [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments							$ 10,000,000			10,000,000
Development and Regulatory First Indication First Milestone [Member] \| License Agreement [Member] \| Mabwell [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments			$ 5,000,000
Development and Regulatory First Indication Second Milestone [Member] \| License Agreement [Member] \| Roche [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment										$ 15,000,000
Development and Regulatory First Indication Second Milestone [Member] \| License Agreement [Member] \| Mabwell [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment									10,000,000
Development and Regulatory Second Indication First Milestone [Member] \| License Agreement [Member] \| Mabwell [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment									5,000,000
Development and Regulatory [Member] \| License Agreement [Member] \| Mabwell [Member] \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment									127,500,000
Development [Member] \| License and Stock Purchase Agreement [Member] \| AbbVie [Member] \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment						18,000,000
Development [Member] \| Merger Agreement [Member] \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment	5,600,000
Commercialization [Member] \| License and Stock Purchase Agreement [Member] \| AbbVie [Member] \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment						45,000,000
Sales-based [Member] \| License and Stock Purchase Agreement [Member] \| AbbVie [Member] \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment						$ 87,500,000
Sales-based [Member] \| License Agreement [Member] \| Roche [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment				$ 120,000,000
Sales-based [Member] \| License Agreement [Member] \| Mabwell [Member] \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment									$ 275,000,000
Sales-based [Member] \| Merger Agreement [Member] \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future milestone payment	$ 20,000,000